Full Text View
Tabular View
No Study Results Posted
Related Studies
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer (OVHM-01)
This study has been terminated.
( Poor recruitment )
Study NCT00889733   Information provided by University Health Network, Toronto

First Received on April 27, 2009.   Last Updated on October 6, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Epithelial Ovarian Cancer
Additional conditions recognized in this trial
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
Intraperitoneal (IP) Cisplatin
Additional drug interventions recognized in this trial
Cisplatin
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
University Health Network, Toronto
Princess Margaret Hospital, Canada


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services